OCEANSIDE, Calif., June 06, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today their plans to license Pan Am four additional immunotherapy products developed by the Company.

The immune system's natural capacity to detect and destroy abnormal cells may prevent the development of many cancers. However, cancer cells are sometimes able to avoid detection and destruction by the immune system. Cancer cells may:

-- reduce the expression of tumor antigens on their surface, making it harder for the immune system to detect them -- express proteins on their surface that induce immune cell inactivation -- induce cells in the surrounding environment (microenvironment) to release substances that suppress immune responses and promote tumor cell proliferation and survival

In the past few years, the rapidly advancing field of cancer immunology has produced several new methods of treating cancer, called immunotherapies, which increase the strength of immune responses against tumors. Immunotherapies either stimulate the activities of specific components of the immune system or counteract signals produced by cancer cells that suppress immune responses. These advances in cancer immunotherapy are the result of long-term investments in basic research on the immune system research that continues today by scientists at TSOI.

"The licensing of these additional patent-pending technologies to Pan Am, which includes Cancer Metabolic Detox, innaMune, LymphoBoost, and MemoryMune, are critical components to our overall cancer platform developed in-house by Company scientists. This will give new tools to the physicians at Pan Am to combat different cancers at different levels, along with the administration of StemVacs, our immunotherapy platform," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "Although we recently announced the licensing of our StemVacs platform to Pan Am to treat stages 1-4 in both prostate and breast cancer, these additional therapies will allow for additional protocols to treat additional cancers such as kidney, liver, lung, and melanoma," added Mr. Dixon.

The following products can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

Cancer Metabolic DeTox: By administering Cancer Metabolic DeTox, the innate arm of the immune system has a chance to regenerate. This positions the patient for a better outcome after administration of specific immune stimulating vaccines. innaMune: Is a biological product derived from a tissue culture of blood cells derived from healthy donors. It is a combination of cytokines that maintain activity of innate immune system cells, as well as having the ability to shift M2 macrophages to M1. LymphoBoost: Is a proprietary formulation of Mifepristone, a drug approved for another indication, which we have shown to be capable of stimulating lymphocytes, particularly NK cells and T cells, both critical in maintaining anti-tumor immunity. MemoryMune: Is a product derived from a two-step culture process of donor blood cells. The product MemoryMune reawakens dormant immune memory cells. It is known that many cancer patients possess memory T cells that enter the tumor, however, once inside the tumor these cells are inactivated. MemoryMune contains a unique combination of growth factors specific for immune system cells called "cytokines".

The overarching approach to cancer on our StemVacs platform is as follows:

1. Treat innate immune suppression: Administration of oral apigenin/pterostilbene (Cancer Metabolic DeTox Product) to decrease immune suppressive toxic molecules made by tumor and tumor microenvironment. 2. Treat adaptive immune suppression: Administration of MemoryMune to activate dormant memory cells recognizing the tumor. Administration of LymphoBoost to repair deficient IL-12 production. 3. Stimulation of immune response to cancer stem cells (StemVacs). 4. Consolidation and maintenance of immunity: Cycles of StemVacs, supported by innaMune and LymphoBoost

"At the Pan Am Cancer Treatment Centers, we are committed to providing a multi-disciplinary attack on cancer through concurrently activating multiple arms of the immune system. By working with scientists at TSOI, we are excited to offer to our patients a new spectrum of therapeutic approaches, thus positioning us uniquely amongst cancer immunotherapy," said Dr. Javier Lopez, Chief Executive Officer of the Pan American Cancer Treatment Center. "By combining second generation cellular therapeutics, such as antigen-pulsed dendritic cells, together with natural immune stimulants, we are confident in our ability to provide second to none immunotherapeutic protocols". About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.

About Pan Am Cancer Treatment Center Pan Am Cancer Treatment Center contact information: Telephone: (619) 735-9581 Diego Rivera #2339 suite 108 Zona Rio, Tijuana B.C. 22010 www.cancerimmunotherapy.mxinfo@cancerimmunotherapy.mx

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

CONTACT INFORMATION

Therapeutic Solutions International, Inc. ir@tsoimail.com